THELMA

OFFICIAL TITLE: T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.

PROJECT DETAILS

PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.

THE PRIMARY GOAL IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION OF T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (MBC) PATIENTS PREVIOUSLY TREATED WITH TAXANES AND TRASTUZUMAB-BASED THERAPY.

IN ADDITION, PHARMACOKINETIC DATA ON THE COMBINATION OF T-DM1 AND LYPOSOMAL DOXORUBICIN WILL BE OBTAINED.

 

 

THELMA AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

BREAST

I

24

5

Spain, France, Slovenia

N

SITES

COUNTRY

STATUS

Recruitment  closed

ESMO  2019 – DOWNLOAD THE POSTER

ESMO  2019 – DOWNLOAD  LIST OF COI'S

SABCS  2016 – DOWNLOAD THE POSTER

THELMA SITES

SPAIN

Hospital Universitari Vall D'Hebron

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Hospital Clínic i Provincial de Barcelona

FRANCE

Institut Curie

FRANCE

Hôpital Tenon AP-HP

SLOVENIA

Univerzitetni klinicni center Maribor Oddelek za onkologijo

SLOVENIA

Onkološki Inštitut Ljubljana